Cullen/Frost Bankers, Inc. Sage Therapeutics, Inc. Transaction History

Cullen/Frost Bankers, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 05, 2020	SELL	$25.95 - $43.15 $4,281 - $7,119	-165 Closed	0 $0
Q1 2020 May 01, 2020	SELL	$26.15 - $77.24 $732 - $2,162	-28 Reduced 14.51%	165 $5,000
Q4 2019 Feb 06, 2020	SELL	$60.18 - $154.77 $9,327 - $23,989	-155 Reduced 44.54%	193 $14,000
Q3 2019 Nov 01, 2019	SELL	$140.29 - $189.96 $7,295 - $9,877	-52 Reduced 13.0%	348 $49,000
Q2 2019 Aug 01, 2019	SELL	$157.85 - $183.09 $31,570 - $36,618	-200 Reduced 33.33%	400 $73,000
Q1 2019 Apr 30, 2019	BUY	$89.33 - $163.65 $53,598 - $98,190	600 New	600 $95,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.